文献速递血栓与止血

癌症患者偶发性与症状性静脉血栓栓塞结局的系统综述与荟萃分析

Outcomes among patients with cancer and incidental or symptomatic venous thromboembolism: A systematic review and meta-analysis.
PubMed 文献 · J Thromb Haemost · 2021-07-12

该系统综述与荟萃分析纳入3项随机对照试验和20项观察性研究,比较癌症患者偶发性与症状性静脉血栓栓塞的结局。3项RCT的荟萃分析显示,偶发性VTE患者6个月VTE复发率显著低于症状性VTE(RR 0.62,95%CI 0.44-0.87),大出血风险数值上更高(RR 1.47,95%CI 0.99-2.20),总死亡率无差异。提示两类事件抗凝的风险获益比可能不同。

要点

  • 癌症患者偶发性VTE较症状性VTE的6个月复发风险更低(RR 0.62)。
  • 偶发性VTE大出血风险数值上高于症状性VTE(RR 1.47,95%CI 0.99-2.20)。
  • 偶发性与症状性VTE的总死亡率无差异。

核心结论

  • 在癌症患者中,偶发性VTE较症状性VTE与更低的VTE复发率相关,大出血事件有增加趋势。
  • 偶发性与症状性VTE的抗凝风险获益比可能不同,应在患者管理中加以考虑。

研究设计与样本

  • 系统综述与荟萃分析,检索电子数据库,纳入报告复发性VTE、大出血事件和死亡率的随机对照试验与观察性研究。
  • 共纳入23项研究:3项随机对照试验和20项观察性研究。

主要发现

  • 3项RCT的荟萃分析显示,偶发性VTE患者6个月VTE复发率显著低于症状性VTE患者(RR 0.62,95%CI 0.44-0.87)。
  • 6个月大出血事件风险在偶发性VTE组数值上高于症状性VTE组(RR 1.47,95%CI 0.99-2.20)。
  • 总死亡率在偶发性与症状性VTE之间无差异。

临床怎么用

  • 临床管理中应考虑偶发性与症状性VTE抗凝风险获益比的潜在差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with cancer have an increased risk of venous thromboembolism (VTE) and it is commonly detected incidentally. The outcomes and optimal management for patients with cancer and incidental VTE remain debated. OBJECTIVES: We conducted a systematic review and meta-analysis to evaluate the outcomes in patients with cancer and incidentally detected VTE compared to those with symptomatic events. PATIENTS/METHODS: We searched the electronic databases and included randomized controlled trials (RCTs) and observational studies reporting recurrent VTE, major bleeding events, and mortality in patients with cancer and incidental VTE compared to symptomatic VTE. RESULTS: We included 23 studies for the systematic review: 3 RCTs and 20 observational studies. The meta-analysis of the 3 RCTs showed a significantly lower rate of VTE recurrence at 6 months in patients with incidental VTE compared to those with symptomatic VTE (relative risk [RR] 0.62, 95% confidence interval [CI] 0.44-0.87). The risk of major bleeding events at 6 months was numerically higher with incidental VTE compared to symptomatic VTE (RR 1.47, 95% CI 0.99-2.20). There was no difference in overall mortality. CONCLUSIONS: Among patients with cancer, incidental VTE was associated with a lower rate of VTE recurrence compared to symptomatic VTE, with a trend in increased major bleeding events. The risk-benefit ratio of anticoagulation may differ between incidental and symptomatic events and should be considered in patient management.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Caiano L, Carrier M, Marshall A, et al. Outcomes among patients with cancer and incidental or symptomatic venous thromboembolism: A systematic review and meta-analysis. J Thromb Haemost. 2021. PMID: 34161655. doi:10.1111/jth.15435

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。